A Non-Interventional Retrospective (12 Months) and Prospective (at Least 24 Months) Resource Utilization Study, in the Population of Polish Acromegalic Patients Treated With Somatuline Autogel at Normal (4 Weeks) or Extended (6 or 8 Weeks) Dosing Interval

Ipsen1 site in 1 country150 target enrollmentOctober 2010

ConditionsAcromegaly

Overview

Phase: N/A
Intervention: Not specified
Conditions: Acromegaly
Sponsor: Ipsen
Enrollment: 150
Locations: 1
Primary Endpoint: Percentage variation of Insulin-like growth factor-1 (IGF-1) levels
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate over the 24 month prospective follow up - in everyday clinical practice - resource utilization and effectiveness of the treatment of acromegalic patients in Poland with Somatuline Autogel 120 mg including extended injection intervals.

Registry

clinicaltrials.gov

Start Date

October 2010

End Date

June 2014

Last Updated

7 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Ipsen

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Adult patients with acromegaly treated for at least three injections with Somatuline Autogel 120 mg
•Subjects must be treated for acromegaly for at least 1 year, with medical treatment prior to inclusion. One year historical data must be available

Exclusion Criteria

•Active participation in any interventional or any other non-interventional acromegaly clinical study. Previous participation in observational / post-marketing study of other somatostatin analogue should not be an exclusion criteria